Ticker LaunchIPO · ANVS
Annovis Bio, Inc.
Formerly QR Pharma, Inc.
Annovis Bio, Inc. (ANVS) priced its initial public offering on Jan 30, 2020 at $6.00 per share, raising $12M, and listed on NYSE American. At the IPO price its market capitalization was about $39.1M. ThinkEquity was lead-left underwriter. Duane Morris advised the company and Venable advised the underwriters.
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration, including Alzheimer's disease in Down syndrome, Alzheimer's disease and Parkinson's disease. Its lead compound, ANVS-401, inhibits the synthesis of neurotoxic proteins, and it has a Phase 2a study ongoing in Alzheimer's patients.
- Status
- IPO
- Ticker
- ANVS
- Exchange
- NYSE American
- Priced
- Jan 30, 2020
- IPO price
- $6.00
- Raised
- $12M
- Market cap at IPO price
- $39.1M
- First filed
- Jul 3, 2019
- Underwriters
- ThinkEquity
- Company counsel
- Duane Morris
- Underwriters' counsel
- Venable
- Sector
- Biotech & pharma
- Country / state
- PA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jul 3, 2019
- Latest amendment Jan 24, 2020
- Final prospectus (424B4) Jan 30, 2020
- All filings on EDGAR CIK 1477845
Other Biotech & pharma IPOs in 2020
- Beam Therapeutics Inc.BEAM · Feb 7, 2020 · $180M
- PPD, Inc.PPD · Feb 6, 2020 · $1.62B
- Schrodinger, Inc.SDGR · Feb 6, 2020 · $202M
- Arcutis Biotherapeutics, Inc.ARQT · Jan 31, 2020 · $159.4M
- Black Diamond Therapeutics, Inc.BDTX · Jan 30, 2020 · $201.1M
- Addex Therapeutics Ltd.ADXN · Jan 28, 2020